Publications (Selected)

1. Lamsfus-Calle A, Daniel-Moreno A, Antony JS, Epting T, Heumos L, Baskaran P, Admard J, Casadei N, Latifi N, Siegmund DM, Kormann MSD, Handgretinger R, Mezger M. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin. Sci Rep. 2020 Jun 23;10(1):10133.
2. Daniel-Moreno A, Lamsfus-Calle A, Wilber A, Chambers CB, Johnston I, Antony JS, Epting T, Handgretinger R, Mezger M. Comparative analysis of lentiviral gene transfer approaches designed to promote fetal hemoglobin production for the treatment of β-hemoglobinopathies. Blood Cells Mol Dis. 2020 Sep;84:102456.
3. Lamsfus-Calle A, Daniel-Moreno A, Ureña-Bailén G, Raju J, Antony JS, Handgretinger R, Mezger M. Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches. Blood Rev. 2020 Mar;40:100641.
4. Haque AKM*, Weinmann P*, Biswas S, Handgretinger R, Mezger M, Kormann M, Antony JS. RNA ImmunoGenic Assay: Simple Method for Detecting Immunogenicity of in vitro Transcribed mRNA. Adv Cell Gene Ther. 2020;e79
5. Ureña-Bailén G, Lamsfus-Calle A, Daniel-Moreno A, Raju J, Schlegel P, Seitz C, Atar D, Antony JS, Handgretinger R, Mezger M. CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. Brief Funct Genomics. 2020 May 20;19(3):191-200.
6. Daniel-Moreno A, Lamsfus-Calle A, Raju J, Antony JS, Handgretinger R, Mezger M. CRISPR/Cas9-modified hematopoietic stem cells-present and future perspectives for stem cell transplantation. Bone Marrow Transplant. 2019 Dec;54(12):1940-1950.
7. Lamsfus-Calle A*, Daniel-Moreno A*, Ureña-Bailén G, Raju J, Antony JS, Handgretinger R, Mezger M. Hematopoietic Stem Cell Gene Therapy: The optimal use of Lentivirus and Gene Editing Approaches. Blood Reviews. 2019 15:100641
8. Antony JS*, Latifi N*, Ashiqul Haque AKM, Lamsfus-Calle A, Daniel-Moreno A, Gräter S, Baskarab P, Weinmann P, Mezger M, Handgretinger R, Kormann M (2018) Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors. Mol Cell Pediatr. 2018 14;5(1):9.
9. Antony JS, Haque AKMA, Lamsfus- Calle A, Daniel-Moreno A, Mezger M, Kormann MSD. CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases. Adv Cell Gene Ther. 2018;e10.
10. Vaidyanathan S, Azizian K, Haque AKMA, Henderson J, Hendel A, Shore S, Antony JS, Hogrefe R, Kormann M, Porteus M and McCaffrey A. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce or Prevent Immune Activation Even Without HPLC Purification. Mol Ther Nucleic Acids. 2018 Sep 7;12:530-542.
11. Kormann MSD, Dewerth A, Eichner F, Baskaran P, Hector A, Regamey N, Hartl D, Handgretinger R, Antony JS. Transcriptomic profile of cystic fibrosis patients identifies type I interferon response and ribosomal stalk proteins as potential modifiers of disease severity. PLoS One 2017, 12(8):e0183526
12. Hohwieler M, Illing A, Hermann PC, Mayer T, Stockmann M, Perkhofer L, Eiseler T, Antony JS, et al. Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling. Gut. 2017 Mar;66(3):473-486.
13. Antony JS, Dewerth A, Haque A, Handgretinger R, Kormann MS. Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies. Mol Cell Pediatr. 2015 Dec;2(1):11.
14. Antony JS, Ojurongbe O, Kremsner PG, Velavan TP Lectin complement protein Collectin 11 (CL-K1) and susceptibility to urinary schistosomiasis. PLoS Negl Trop Dis 2015 9: e0003647
15. Antony JS, Ojurongbe O, van Tong H, Ouf EA, Engleitner T, Akindele AA, Sina-Agbaje OR, Adeyeba AO, Kremsner PG, Velavan TP. Mannose-binding lectin and susceptibility to schistosomiasis. J Infect Dis 2013 207: 1675-1683